Pooled analyses show that although fructose may increase total cholesterol , uric acid , and postpr and ial triglycerides in isocaloric replacement for glucose , it does not appear to be any worse than glucose in its effects on other aspects of the lipid profile , insulin , or markers of nonalcoholic fatty liver disease .
It may also have important advantages over glucose for body weight , glycemic control , and blood pressure .
SUMMARY Depending on the cardiometabolic endpoint in question , fructose has variable effects when replacing glucose .
PURPOSE OF REVIEW Fructose is seen as uniquely contributing to the p and emics of obesity and its cardiometabolic complications .
Much of the evidence for this view derives from the unique biochemical , metabolic , and endocrine responses that differentiate fructose from glucose .
To underst and whether these proposed mechanisms result in clinical ly meaningful modification of cardiovascular risk in humans , we up date a series of systematic review s and meta-analyses of controlled feeding trials to assess the cardiometabolic effects of fructose in isocaloric replacement for glucose .
No difference between high-fructose and high-glucose diets on liver triacylglycerol or biochemistry in healthy overweight men.
BACKGROUND & AIMS Diets high in fructose have been proposed to contribute to nonalcoholic fatty liver disease . We compared the effects of high-fructose and matched glucose intake on hepatic triacylglycerol ( TAG ) concentration and other liver parameters . DESIGN In a double-blind study , we r and omly assigned 32 healthy but central ly overweight men to groups that received either a high-fructose or high-glucose diet ( 25 % energy ) . These diets were provided during an initial isocaloric period of 2 weeks , followed by a 6-week washout period , and then again during a hypercaloric 2-week period . The primary outcome measure was hepatic level of TAG , with additional assessment s of TAG levels in serum and soleus muscle , hepatic levels of adenosine triphosphate , and systemic and hepatic insulin resistance . RESULTS During the isocaloric period of the study , both groups had stable body weights and concentrations of TAG in liver , serum , and soleus muscle . The high-fructose diet produced an increase of 22 ± 52 μmol/L in the serum level of uric acid , whereas the high-glucose diet led to a reduction of 23 ± 25 μmol/L ( P < .01 ) . The high-fructose diet also produced an increase of 0.8 ± 0.9 in the homeostasis model assessment of insulin resistance , whereas the high-glucose diet produced an increase of only 0.1 ± 0.7 ( P = .03 ) . During the hypercaloric period , participants in the high-fructose and high-glucose groups had similar increases in weight ( 1.0 ± 1.4 vs 0.6 ± 1.0 kg ; P = .29 ) and absolute concentration of TAG in liver ( 1.70 % ± 2.6 % vs 2.05 % ± 2.9 % ; P = .73 ) and serum ( 0.36 ± 0.75 vs 0.33 ± 0.38 mmol/L ; P = .91 ) , and similar results in biochemical assays of liver function . Body weight changes were associated with changes in liver biochemistry and concentration of TAGs . CONCLUSIONS In the isocaloric period , overweight men who were on a high-fructose or a high-glucose diet did not develop any significant changes in hepatic concentration of TAGs or serum levels of liver enzymes . However , in the hypercaloric period , both high-fructose and high-glucose diets produced significant increases in these parameters without any significant difference between the 2 groups . This indicates an energy-mediated , rather than a specific macronutrient-mediated , effect . Clinical trials.gov no : NCT01050140
Pooled analyses show that although fructose may increase total cholesterol , uric acid , and postpr and ial triglycerides in isocaloric replacement for glucose , it does not appear to be any worse than glucose in its effects on other aspects of the lipid profile , insulin , or markers of nonalcoholic fatty liver disease .
It may also have important advantages over glucose for body weight , glycemic control , and blood pressure .
SUMMARY Depending on the cardiometabolic endpoint in question , fructose has variable effects when replacing glucose .
PURPOSE OF REVIEW Fructose is seen as uniquely contributing to the p and emics of obesity and its cardiometabolic complications .
Much of the evidence for this view derives from the unique biochemical , metabolic , and endocrine responses that differentiate fructose from glucose .
To underst and whether these proposed mechanisms result in clinical ly meaningful modification of cardiovascular risk in humans , we up date a series of systematic review s and meta-analyses of controlled feeding trials to assess the cardiometabolic effects of fructose in isocaloric replacement for glucose .